Structure-Activity Relations for Neurotransmitter Receptor Agonists and Antagonists

Part of the Handbook of Psychopharmacology book series (HBKPS, volume 2)


Until fairly recently, the only way of discovering anything about the nature of postsynaptic receptors for neurotransmitters was the time-honored method of studying the structure-activity relationships of agonists and antagonists. This information was usually incidental to the main practical preoccupation of finding compounds that were pharmacologically more active and specific. The nature of the information obtainable about receptors by this method is, of course, limited. One may show, for example, that in a particular drug certain chemical groups are essential for activity. Depending on the nature of these groups, it is possible to hypothesize binding via ionic or hydrogen bonds and van der Waals or hydrophobic interactions. However, the nature of the receptor components through which these interactions occur is in most cases totally unknown. There is also the problem that unless one works with conformationally rigid moelcules the actual shape of the drug on interaction with the receptor is uncertain. In recent years, more direct attempts have been made to learn something of the chemical nature of various receptors by actual isolation of the macromolecules thought to comprise the receptor material. An extensive review of earlier work in this area using a variety of reversible and irreversible agonists and antagonists has been published (Ehrenpreis et al., 1969). More recent studies are dealt with elsewhere in this series (Hollenberg and Cuatrecasas, Chap. 5, this volume; Changeux, Chap. 7, Vol. 6; Snyder, Chap. 6, Vol. 5).


Adenylate Cyclase Muscarinic Receptor Prefer Conformation Sympathomimetic Amine Helix Aspersa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson, D. W., Barrett, P. A., Billinghurst, J. W., Green, A. F., Jones, T.S. G.: 1951. Geometrical Isomers in a Series of Antihistamines, Nature 168: 204–205.PubMedCrossRefGoogle Scholar
  2. Ahlquist, R. P.: 1948. A study of adrenotropic receptors, Am. J. Physiol. 153: 586–600.PubMedGoogle Scholar
  3. Ahlquist, R. P.: 1968. Agents which block adrenergic A-receptors, in: Annual Review of Pharamacology, Vol 8 ( H. W. Elliott, ed.), pp. 259–272, Annual Reviews, Inc., Palo Alto, Calif.Google Scholar
  4. Ainsworth, C.: 1958. Substituted β-aminoethylindazoles, J. Am. Chem. Soc. 80: 965–967.CrossRefGoogle Scholar
  5. Aizenshtat, Z., Klein, E., Weiler-Feilchenfeld, H., Bergmann, E. D.: 1972. Conformational studies on xanthene, thioxanthene and acridan, Israel J. Chem. 10: 753–763.Google Scholar
  6. Anden, N. E., Roos, B. E., Werdinius, B.: 1964. Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum, Life Sci. 3: 149–158.CrossRefGoogle Scholar
  7. Anden, N. E., Rubenson, A., Fuxe, K., Hokfelt, T.: 1967. Evidence for dopamine receptor stimulation by apomorphine, J. Pharm. Pharmacol. 19: 627–629.PubMedCrossRefGoogle Scholar
  8. Anden, N. E., Butcher, S. G., Corrodi, H., Fuxe, K., Ungerstedt, U.: 1970. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics, Eur. J. Pharmacol. 11: 303–314.PubMedCrossRefGoogle Scholar
  9. Ariens, E. J.: 1963. in: First International Pharmacological Meeting Stockholm 1961, Vol. 7, p. 247, Macmillan, New York.Google Scholar
  10. Ariens, E. J.: 1967. The structure-activity relationships of A-adrenergic drugs and A-adrenergic blocking drugs, Ann. N.Y. Acad. Sci. 139: 606–631.PubMedCrossRefGoogle Scholar
  11. Ariens, E. J.: 1971. A general introduction to the field of drug design, in: Drug Design, Vol. 1 ( E. J. Ariens, ed.), pp. 1–270, Academic Press, New York.Google Scholar
  12. Ariens, E. J., Simonis, A. M.: 1964. A molecular basis for drug action, J. Pharm. Pharmacol. 16: 137–157.CrossRefGoogle Scholar
  13. Aroney, M. J., Hoskins, G. M., Lefevre, R. J. W.: 1968. Molecular polarisability: The conformations as solutes of phenothiazine and of N-methyl and N-phenylphenothiazine, J. Chem. Soc. (B) 1968: 1206–1208.Google Scholar
  14. Ash, A. S. F., Schild, H. O.: 1966. Receptors mediating some actions of histamine, Brit. J. Pharmacol. 27: 427–439.PubMedGoogle Scholar
  15. Bachrach, W. H.: 1958. Anticholinergic drugs: Survey of the literature and some experimental observations, Am. J. Digest. Dis. 3: 743–799.PubMedCrossRefGoogle Scholar
  16. Baker, R. W., Chothia, C. H., Pauling, P., Petcher, T. J.: 1971. Structure and activity of muscarinic stimulants, Nature 230: 439–445.PubMedCrossRefGoogle Scholar
  17. Banister, J., Whittaker, V. P.: 1951. Pharmacological activity of the carbon analogue of acetylcholine, Nature 167: 605–606.PubMedCrossRefGoogle Scholar
  18. Barger, G., Dale, H. H.: 1910. Chemical structure and sympathomimetic action of amines, J. Physiol. 41: 19–59.PubMedGoogle Scholar
  19. Barlow, R. B.: 1964. Introduction to Chemical Pharamacology, 2nd ed., pp. 344–377, Wiley, New York.Google Scholar
  20. Barlow, R. B., Kahn, I.: 1959a. Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparations, Brit. J. Pharmacol. 14: 99–107.PubMedGoogle Scholar
  21. Barlow, R. B., Kahn, I.: 1959b. Actions of some analogues of 5-hydroxytryptamine on the isolated rat uterus and the rat fundus strip preparations, Brit. J. Pharmacol. 14: 265–272.PubMedGoogle Scholar
  22. Barlow, R. B., Scott, K. A., Stephenson, R. P.: 1963. An attempt to study the effects of chemical structure on the affinity and efficacy of compounds related to acetylcholine, Brit. J. Pharmacol. 21: 509–522.PubMedGoogle Scholar
  23. Barrett, A. M.: 1972. Design of α-blocking drugs, in: Drug Design, Vol. III. ( E. J. Ariens, ed.), pp. 205–228, Academic Press, New York.Google Scholar
  24. Beckett, A. H., Harper, N. J., Clitherow, J. W., Lesser, E.: 1961. Muscarinic receptors, Nature 189: 671–673.PubMedCrossRefGoogle Scholar
  25. Beers, W. H., Reich, E.: 1970. Structure and activity of acetylcholine, Nature 228: 917–922.PubMedCrossRefGoogle Scholar
  26. Bell, C., Lang, W. J.: 1973. Neural dopaminergic vasodilator control in the kidney, Nature 246: 27–29.Google Scholar
  27. Belleau, B.: 1965. In: Isotopes in Pharmacology (L. Roth, ed.), p. 469, University of Chicago Press, Chicago.Google Scholar
  28. Belleau, B.: 1967. Stereochemistry of adrenergic receptors: Newer concepts on the molecular mechanism of action of catecholamines and antiadrenergic drugs at the receptor level, Ann. N.Y. Acad. Sci. 139: 580–605.PubMedCrossRefGoogle Scholar
  29. Bergin, R., Carlstrom, D.: 1968. The crystal structure of dopamine hydrochloride, Acta Crystallog. B24: 1506–1510.CrossRefGoogle Scholar
  30. Berridge, M. J.: 1972. The mode of action of 5-hydroxytryptamine, J. Exp. Biol. 56: 311–321.PubMedGoogle Scholar
  31. Berridge, M. J., Patel, N. E.: 1968. Insect salivary glands: Stimulation of fluid secretion by 5-hydroxytryptamine and adenosine 3’,5’-monophosphate, Science 162: 462–463.PubMedCrossRefGoogle Scholar
  32. Bertaccini, G., Zamboni, P.: 1961. The relative potency of 5-hydroxytryptamine-like substances, Arch. Int. Pharmacodyn. 133: 138–156.PubMedGoogle Scholar
  33. Beveridge, D. L., Radna, R. J.: 1971. A quantum theoretical study of the molecular electronic structure of acetylcholine, J. Am. Chem. Soc. 93: 3759–3764.PubMedCrossRefGoogle Scholar
  34. Biscoe, T. J., Curtis, D. R., Ryall, R. W.: 1966. An investigation of catecholamine receptors of spinal interneurones, Int. J. Neuropharmacol. 5: 429–434.PubMedCrossRefGoogle Scholar
  35. Black, J. M., Duncan, W. A. M., Shanks, R. G.: 1965. Comparison of some properties of pronethalol and propranolol, Brit. J. Pharmacol. 25: 577–591.PubMedGoogle Scholar
  36. Black, J. W., Duncan, W. A. M., Durant, C. J., Ganellin, C. R., Parsons, E. M.: 1972. Definition and antagonism of histamine H2-receptors, Nature 236: 385–390.PubMedCrossRefGoogle Scholar
  37. Blinks, J. R.: 1967. Evaluation of the cardiac effects of several α-adrenergic blocking agents, Ann. N.Y. Acad. Sci. 139: 673–685.PubMedCrossRefGoogle Scholar
  38. Bloom, B. M., Goldman, I. M.: 1966. The nature of catecholamine-adenine mononucleotide interactions in adrenergic mechanisms, in: Advances in Drug Research, Vol. 3 ( N. J. Harper, A. B. Simmonds, eds.), pp. 121–169, Academic Press, London.Google Scholar
  39. Bloom, F. E., Costa, E., Salmoiraghi, G. C.: 1964. Analysis of individual rabbit olfactory bulb neuron responses to the microelectrophoresis of acetylcholine, norepinephrine and serotonin synergists and antagonists, J. Pharmacol. Exp. Ther. 146: 16–23.PubMedGoogle Scholar
  40. Boakes, R. J., Bradley, P. B., Brookes, N., Candy, J. M., Wolstencroft, J. H.: 1971. Actions of noradrenaline, other sympathomimetic amines and antagonists on neurones in the brain stem of the cat, Brit. J. Pharmacol. 41: 462–479.Google Scholar
  41. Born, G. V. R.: 1971. In: Effects of Drugs on Cellular Control Mechanisms (B. R. Rabin, R. B. Freedman, eds.), pp. 237–257, Macmillan, London.Google Scholar
  42. Bovet, D.: 1950. Introduction to antihistamine agents and antergan derivatives, Ann. N.Y. Acad. Sci. 50: 1089–1126.PubMedCrossRefGoogle Scholar
  43. Bovet, D., Bovet-Nitti, F.: 1948. In: Medicaments du Systeme Nerveux Vegetatif, pp. 222–237, Karger, Basel.Google Scholar
  44. Bovet, D., Bovet-Nitti, F., Marini-Bettolo, G. B.: (eds.), 1959. Curare and Curare-like Agents, Elsevier, Amsterdam.Google Scholar
  45. Brotzu, G.: 1970. Inhibition by chlorpromazine of the effects of dopamine on the dog kidney, J. Pharm. Pharmacol. 22: 664–667.PubMedCrossRefGoogle Scholar
  46. Brown, J. H., Makman, M. H.: 1972. Stimulation by dopamine of adenylate cyclase in retinal homogenates and of adenosine 3’,5’-cyclic monphosphate formation in intact retina, Proc. Natl. Acad. Sci. 69: 539–543.PubMedCrossRefGoogle Scholar
  47. Brown, J. H., Makman, M. H.: 1973. Influence of neuroleptic drugs and apomorphine on dopamine-sensitive adenylate cyclase of retina, J. Neurochem. 21: 477–479.PubMedCrossRefGoogle Scholar
  48. Burgen, A. S. V.: 1965. The role of ionic interaction at the muscarinic receptor, Brit. J. Pharmacol. 25: 4–17.PubMedGoogle Scholar
  49. Burgen, A, S. V., Hiley, C. R., Young, J. M.: 1974a. The binding of 3H- propylbenzilylcholine mustard by longitudinal muscle strips from guinea-pig small intestine, Brit. J. Pharmacol. 50: 145–151.Google Scholar
  50. Burgen, A. S. V., Hiley, C. R., Young, J. M.: 1974b. The properties of muscarinic receptors in mammalian cerebral cortex, Brit. J. Pharmacol., 51: 279–285.Google Scholar
  51. Burger, A., Bernabe, M., Collins, P. W.: 1970. (4-Imidazolyl) Cyclopropylamine, J. Med. Chem. 13: 33–35.Google Scholar
  52. Burks, T. F., Long, J. P., Darko, L. L., Cannon, J. G.: 1965. Evaluation of n-methoxy substitution in cholinergic agents, Fed. Proc. 24: 611.Google Scholar
  53. Burns, J. J., Colville, K. I., Lindsay, L. A., Salvador, R. A.: 1964. Blockade of some metabolic effects of catecholamines by N-isopropyl methoxamine (B. W. 61–43), J. Pharmacol. Exp. Ther. 144: 163–171.PubMedGoogle Scholar
  54. Burns, T. W., Langley, P. E., Robison, G. A.: 1971. Adrenergic receptors and cyclic AMP: Regulation of human adipose tissue lipolysis, Ann. N.Y. Acad. Sci. 185: 115–128.PubMedCrossRefGoogle Scholar
  55. Cameron, W. M., Tainter, M. L.: 1936. Comparative actions of sympathomimetic compounds: Bronchiodilator actions in bronchial spasms induced by histamine, J. Pharmacol. Exp. Ther. 57: 152–169.Google Scholar
  56. Campaigne, E., Knapp, D. R., Neiss, E. S., Bosin, T. R.: 1970. Biologically active benzothiophene derivatives, in: Advances in Drug Research, Vol. 5 ( N. J. Harper, A. B. Simmonds, eds.), pp. 1–54, Academic Press, London.Google Scholar
  57. Canepa, F. G., Pauling, P. J., Sorum, H.: 1966. Structure of acetylcholine and other substrates of cholinergic systems, Nature 210: 907–909.PubMedCrossRefGoogle Scholar
  58. Cannon, J. G., Long, J. P.: 1967. Postganglionic parasympathetic depressants, in: Drugs Affecting the Peripheral Nervous System ( A. Burger, ed.), pp. 133–148, Dekker, New York.Google Scholar
  59. Carlsson, A., Lindqvist, M.: 1963. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol. Toxicol. 20: 140–144.CrossRefGoogle Scholar
  60. Carlsson, A., Fuxe, K., Hamberger, B., Lindqvist, M.: 1966. Biochemical and histochem- ical studies of the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons, Acta Physiol. Scand. 67: 481–497.PubMedCrossRefGoogle Scholar
  61. Carlstrom, D., Bergin, R.: 1967. The crystal structure of noradrenaline hydrochloride, Acta Crystallog. 23: 313–319.CrossRefGoogle Scholar
  62. Carlstrom, D., Bergin, R., Falkenberg, G.: 1973. Molecular characteristics of biogenic monoamines and their analogs, Quart. Rev. Biophys. 6: 257–310.CrossRefGoogle Scholar
  63. Carr, L. A., Moore, K. E.: 1970. Effects of amphetamine on the contents of norepinephrine and its metabolites in the effluent of perfused cerebral ventricles of the cat, Biochem. Pharmacol. 19: 2361–2374.PubMedCrossRefGoogle Scholar
  64. Casy, A. F., Ison, R. R., Ham, N. S.: 1970. The conformation of histamine in solution: Nuclear magnetic resonance study, Chem. Commun. 1970: 1343–1344.Google Scholar
  65. Chang, H. C., Gaddum, J. H.: 1933. Choline esters in tissue extracts, J. Physiol. 79: 255–285.PubMedGoogle Scholar
  66. Chothia, C.: 1970a. Interaction of acetylcholine with different cholinergic nerve receptors, Nature 225: 36–38.PubMedCrossRefGoogle Scholar
  67. Chothia, C.: 1970b. Structure-activity relationships of some muscarinic agonists: A reply to Shefter and Triggle, Nature 227: 1355–1356.PubMedCrossRefGoogle Scholar
  68. Chothia, C., Pauling, I.: 1968. Conformations of acetylcholine, Nature 219: 1156–1157.PubMedCrossRefGoogle Scholar
  69. Chothia, C., Pauling, P.: 1970. The conformation of cholinergic molecules at nicotinic nerve receptors, Proc. Natl. Acad. Sci. 65: 477–482.PubMedCrossRefGoogle Scholar
  70. Cole, B., Robison, G. A., Hartmann, R. C.: 1971. Studies on the Role of Cyclic AMP in Platelet Function, Ann. N.Y. Acad. Sci. 185: 477–487.PubMedCrossRefGoogle Scholar
  71. Colhoun, E. H.: 1963. Synthesis of 5-hydroxytryptamine in the American cockroach, Experientia 19: 9–10.PubMedCrossRefGoogle Scholar
  72. Corrodi, H., Persson, H., Carlsson, A., Roberts, J.: 1963. A new series of substances which block the adrenergic a-receptors, J. Med. Chem. 6: 751–755.PubMedCrossRefGoogle Scholar
  73. Coyle, J. T., Snyder, S. H.: 1969. Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action, Science 166: 899–901.PubMedCrossRefGoogle Scholar
  74. Cuello, A. C., Horn, A. S., Mackay, A. V. P., Iversen, L. L.: 1973. Catecholamines in the median eminence: New evidence for a major noradrenergic input, Nature 243: 465–467.PubMedCrossRefGoogle Scholar
  75. Culvenor, C. C. J., Ham, N. S.: 1966. The proton magnetic resonance spectrum and conformation of acetylcholine, Chem. Commun. 1966: 537–539.Google Scholar
  76. Cushley, R. J., Mautner, H. G.: 1970. N.M.R. studies on the conformation of acetylcholine isologues, Tetrahedron 26: 2151–2159.CrossRefGoogle Scholar
  77. Cuthbert, A. W., Young, J. M.: 1973. The number of muscarinic receptors in chick amnion muscle, Brit. J. Pharmacol. 49: 498–505.Google Scholar
  78. Dale, H. H.: 1906. On some physiological actions of ergot, J. Physiol. 34: 163–206.PubMedGoogle Scholar
  79. Dale, H. H.: 1953. Adventures in Physiology, Pergamon Press, London.Google Scholar
  80. Dalgliesh, C. E., Toh, C. C., Work, T. S.: 1953. Fractionation of the smooth muscle stimulants present in extracts of gastro-intestinal tract: Identification of 5-hydroxytryptamine and its distinction from substance P, J. Physiol. 120: 298–310.PubMedGoogle Scholar
  81. Daprada, M., Pletscher, A.: 1966. Acceleration of cerebral dopamine turnover by chlorpromazine, Experientia 22: 465–466.CrossRefGoogle Scholar
  82. Dollery, C. T., Paterson, J. W., Conolly, M. E.: 1969. Clinical pharmacology of beta receptor blocking drugs, Clin. Pharmacol. Ther. 10: 765–799.Google Scholar
  83. Dorignac-Calas, M. R., Marsau, P.: 1972. Structure cristalline du chlorhydrate de chloro-3 (dimethylamino-3’propyl)-10-phenothiazine, Comp. Rend. Acad. Sei. Paris 274: 1806–1809.Google Scholar
  84. Dunitz, J. D., Eser, H., Strickler, P.: 1964. Die Konfiguration des physiologisch Wirksamen 2-Chloro-9-(w-dimethylaminopropyliden)-thioxanthens, Helv. Chim. Acta 47: 1897–1902.CrossRefGoogle Scholar
  85. Ehrenpreis, S., Fleisch, J. H., Mittag, T. W.: 1969. Approaches to the molecular nature of pharmacological receptors, Pharmacol. Rev. 21: 131–181.PubMedGoogle Scholar
  86. Ellenbroek, B. W. J., van Rossum, J. N.: 1960. Absolute configuration and parasympathomimetic activity—Chemistry and pharmacology of acetyl-γ-methyl choline, Arch. Int. Pharmacodyn. 125: 216–220.PubMedGoogle Scholar
  87. Erlenmeyer, H., Lobeck, H.: 1937. Darstellung und Eigenschaften des Acetyl-β-cholin, Helv. Chim. Acta 20: 142–150.CrossRefGoogle Scholar
  88. Ernst, A. M.: 1967. Mode of action of apomorphine and D-amphetamine for gnawing compulsion in rats, Psychopharmacologia 10: 316–323.PubMedCrossRefGoogle Scholar
  89. Erspamer, V.: 1940. Pharmakologische Studien über Enteramin. I, Naunyn-Schmiedberg’s Arch. Exp. Pathol. Pharmakol. 196: 343–365.CrossRefGoogle Scholar
  90. Erspamer, V.: 1954. II sistema cellulare enterocromaffine e L’enteramina (5-idrossitriptamina), Rend. Sei. Farm. 1: 1–193.Google Scholar
  91. Erspamer, V.: 1966. Bioassay of indoleaklyamines, in: 5-Hydroxytryptamine and Related Indolealkylamines (O. Elchler, A. Farah, eds.), pp. 132–181, Vol. 19 of Handbook of Experimental Pharmacology, Springer, Berlin.Google Scholar
  92. Eugster, C. H.: 1959. Synthese and pharmakologische Eigenschaften des Desmethylmus- carones und der stereoisomeren Desmethylmuscarine Die Basen starken der isomeren Normuscarine, Helv. Chim. Acta 42: 1177–1189.CrossRefGoogle Scholar
  93. Everett, A. J., Laue, L. A., Wilkinson, S.: 1970. Revision of the structures of (+)-tubocurarine chloride and (+)-chondrocurine, Chem. Commun. 1970: 1020–1021.Google Scholar
  94. Fellman, J. H., Fujita, T. S., Belber, C. J.: 1962. β-Dihydro-δ-Hydroxytryptamine, Biochem. Pharmacol. 11: 557–561.Google Scholar
  95. Fewtrell, C. M. S., Rang, H. P.: 1973. Labelling cholinergic receptors in smooth muscle, in: Drug Receptors ( H. P. Rang, ed.), pp. 211–224, Macmillan, London.Google Scholar
  96. Freyhan, F. A.: 1961. In: Extrapyramidal System and Neuroleptics (J. M. Bordeleau, ed.), pp. 483–486, Editions Psychiatriques, Montreal.Google Scholar
  97. Friedman, H. L.: 1967. Postganglionic parasympathetic stimulants, in: Drugs Affecting the Peripheral Nervous System, ( A. Burger, ed.), pp. 79–131, Dekker, New York.Google Scholar
  98. Furchgott, R. F.: 1972. The classification of adrenoceptors (adrenergic receptors): An evaluation from the standpoint of receptor theory, in: Catecholamines, (H. Blaschko, E. Muscholl, eds.), pp. 283–335, Vol. 33 of Handbook of Experimental Pharmacology, Springer, Berlin.Google Scholar
  99. Fuxe, K.: 1965. Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monamine nerve terminals in the central nervous system, Acta Physiol. Scand. 64:37–85 (Suppl. 247 ).Google Scholar
  100. Gaddum, J. H., Hameed, K. A.: 1954. Drugs which antagonize δ-hydroxytryptamine, Brit. J. Pharmacol. 9: 240–248.PubMedGoogle Scholar
  101. Gaddum, J. H., Paasonen, M. K.: 1955. The use of some molluscan hearts for the estimation of 5-hydroxytryptamine, Brit. J. Pharmacol. 10: 474–483.PubMedGoogle Scholar
  102. Gaddum, J. H., Picarelli, Z.: 1957. Two kinds of tryptamine receptors, Brit. J. Pharmacol. 12: 323–328.PubMedGoogle Scholar
  103. Garattini, S., Valzelli, L.: 1965. Serotonin, Elsevier, Amsterdam.Google Scholar
  104. Gearien, J. E.: 1970. Cholinergics and anticholinesterases, in: Medicinal Chemistry, Part II, 3rd ed. ( A. Burger, ed.), pp. 1296–1313, Wiley-Interscience, New York.Google Scholar
  105. Geiger, W. B., Alpers, H.: 1964. Properties of an acetylated derivative of trimethylamine oxide, Arch. Int. Pharmacodyn. 148: 352–358.PubMedGoogle Scholar
  106. Giesecke, J.: 1973. The crystal and molecular structure of apomorphine hydrochloride hydrate, Acta Crystallog. B29: 1785–1791.CrossRefGoogle Scholar
  107. Gill, E. W., Rang, H. P.: 1966. An alkylating derivative of benzilycholine with specificand long-lasting parasympatholytic activity, Mol. Pharmacol. 2: 284–297.PubMedGoogle Scholar
  108. Glowinski, J.: 1970. Effects of amphetamine on various aspects of catecholamine metabolism in the central nervous system of the rat, in: Amphetamines and Related Compounds ( E. Costa, S. Garattini, eds.), pp. 301–316, Raven Press, New York.Google Scholar
  109. Goldberg, L. I., Sonneville, P. F., Mcnay, J. L.: 1968. An investigation of the structural requirements for dopamine-like renal vasodilation: Phenylethylamines and apomorphine, J. Pharmacol. Exp. Ther. 163: 188–197.PubMedGoogle Scholar
  110. Goodman, L. S., Gilman, A.: 1970. The Pharmacological Basis of Therapeutics, 4th ed., Macmillan, New York.Google Scholar
  111. Gordon, M.: 1967. Phenothiazines, in: Psychopharmacological Agents, Vol. 11, ( M. Gordon, ed.), pp. 1–198, Academic Press, New York.Google Scholar
  112. Green, A. L.: 1967. Activity correlations and the mode of action of aminoalkylphenothiazine tranquillizers, J. Pharm. Pharmacol. 19: 207–208.PubMedCrossRefGoogle Scholar
  113. Greenberg, M. J.: 1960. Structure-activity relationship of tryptamine analogues on the heart of Venus mercenaria, Brit. J. Pharmacol. 15: 375–388.PubMedGoogle Scholar
  114. Gunn, J. A., Gurd, M. R.: 1940. The action of some amines related to adrenaline: Cyclohexylalkylamines, J. Physiol. 97: 453–470.PubMedGoogle Scholar
  115. Gyermek, L.: 1961. β-Hydroxy tryptamine antagonists, Pharmacol. Rev. 13: 399–439.Google Scholar
  116. Gyermek, L.: 1966. Drugs which antagonize 5-hydroxytryptamine and related indolealkylamines, in: δ-Hydroxytryptamine and Related Indolealkylamines (O. Eichler, A. Farah, eds.), pp. 471–528, Vol. 19 of Handbook of Experimental Pharmacology, Springer, Berlin.Google Scholar
  117. Gyermek, L., Bindler, E.: 1962. Action of indole alkylamines and amidines on the inferior mesenteric ganglion of the cat, J. Pharmacol. Exp. Ther. 138: 159–164.PubMedGoogle Scholar
  118. Gyermek, L., Nador, K.: 1957. The pharmacology of tropane compounds in relation to their steric structure, J. Pharm. Pharmacol. 9: 209–229.PubMedCrossRefGoogle Scholar
  119. Gyermek, L., Unna, K. R.: 1958. Relation of structure of synthetic muscarines and muscarones to their pharmacological action, Proc. Soc. Exp. Biol. Med. 98: 882–885.PubMedGoogle Scholar
  120. Harms, A. F., Nauta, W. T.: 1960. The effects of alkyl substitution on drugs. 1. Substituted dimethylaminoethyl benzhydryl ethers, J. Med. Pharm. Chem. 2: 57–77.PubMedCrossRefGoogle Scholar
  121. Harrison, D. C.: 1971. Circulatory Effects and Clinical Uses of Beta-Adrenergic Blocking Drugs, Excerpta Medica, Amsterdam and London.Google Scholar
  122. Haylett, D. G., Jenkinson, D. H.: 1972. Effects of noradrenaline on potassium efflux, membrane potential and electrolyte levels in tissue slices prepared from guinea-pig liver, J. Physiol. 225: 721–750.PubMedGoogle Scholar
  123. Hebb, C. O., Krnjevic, K.: 1962. Neurochemistry (K. A. C. Elliot, I. H., Page, J. H. Quastel, eds.), pp. 452–521, Thomas, Springfield, 111.Google Scholar
  124. Hiley, C. R., Burgen, A. S. V.: 1974. The distribution of muscarinic receptor sites in the nervous system of the dog, J. Neurochem. 22: 159–162.PubMedCrossRefGoogle Scholar
  125. Hiley, C. R., Young, J. M., Burgen, A. S. V.: 1972. Labelling of cholinergic receptors in subcellular fractions from rat cerebral cortex, Biochem. J. 127: 86 P.Google Scholar
  126. Holton, P., Ing, H. R.: 1949. Specificity of the trimethylammonium group in acetylcholine, Brit. J. Pharmacol. 4: 190–196.PubMedGoogle Scholar
  127. Horn, A. S., Snyder, S. H.: 1971. Chlorpromazine and dopamine: Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs, Proc. Natl. Acad. Sci. 68: 2325–2328.PubMedCrossRefGoogle Scholar
  128. Horn, A. S., Cuello, A. C., Miller, R. J.: 1974. Dopamine in the mesolimbic system of the rat brain: Endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity, J. Neurochem. 22: 265–270.PubMedCrossRefGoogle Scholar
  129. Hornykiewicz, O.: 1966. Dopamine and brain function, Pharmacol. Rev. 18: 925–964.PubMedGoogle Scholar
  130. Howe, R.: 1963. Structure-activity relationships of some α-adrenergic blocking agents, Biochem. Pharmacol. Suppl. 12: 85–86.CrossRefGoogle Scholar
  131. Hunt, C. C., Kuffler, S. W.: 1950. Pharmacology of the neuromuscular junction, Pharmacol. Rev. 2: 96–120.Google Scholar
  132. Hunt, R., Renshaw, R. R.: 1925. On some effects of arsonium, stibonium, phosphonium and sulfonium compounds on the autonomic nervous system, J. Pharmacol. Exp. Ther. 25: 315–355.Google Scholar
  133. Hunt, R., Renshaw, R. R.: 1932. Thio and thiomethyl ammonium compounds, J. Pharmacol. Exp. Ther. 44: 151–169.Google Scholar
  134. Hunt, R., Renshaw, R. R.: 1933. Effects of some quaternary ammonium and analogous compounds on the autonomic nervous system, J. Pharmacol. Exp. Ther. 48: 51–66.Google Scholar
  135. Hunt, R., Taveau, R. de M.: 1906. On the physiological action of certain cholin derivatives and new methods for determining cholin, Brit. Med. J. 2: 1788–1791.CrossRefGoogle Scholar
  136. Hunt, R., Taveau, R. de M.: 1909. On the relation between the toxicity and chemical constitution of a number of derivatives of choline and analogous compounds, J. Pharmacol. Exp. Ther. 1: 303–339.Google Scholar
  137. Huttrer, C. P.: 1947. Chemistry of antihistamine substances, Enzymologia 12: 277–332.Google Scholar
  138. Idson, B.: 1950. Antihistamine drugs, Chem. Rev. 47: 307–527.CrossRefGoogle Scholar
  139. Ing, H. R.: 1936. The curariform action of onium salts, Physiol. Rev. 16: 527–544.Google Scholar
  140. Ing, H. R.: 1946. Synthetic substitutes for atropine, Brit. Med. Bull. 4: 91–95.PubMedGoogle Scholar
  141. Ing, H. R.: 1949. The structure-action relationships of the choline group, Science 109: 264–266.PubMedCrossRefGoogle Scholar
  142. Ing, H. R.: 1956. Structure-action relationships of hypotensive drugs, in: Hypotensive Drugs ( M. Harrington, ed.), pp. 7–22, Pergamon Press, Oxford.Google Scholar
  143. Ing, H. R., Kovdik, P., Tudor-Williams, D. P. H.: 1952. The structure-action relationships of the choline group, Brit. J. Pharmacol. 7: 103–116.PubMedGoogle Scholar
  144. Ison, R. R., Partington, P., Roberts, G. C. K.: 1973. The conformation of catecholamines and related compounds in solution, Mol. Pharmacol. 9: 756–765.PubMedGoogle Scholar
  145. Jacob, J., Marszak, I., Bardisa, L., Marszak-Fleury, A., Epsztein, R.: 1952. The relation of structure to activity in certain acetylcholine, ethylene and saturated derivatives of choline and acetylcholine. Arch. Int. Pharmacodyn. 91: 303–321.PubMedGoogle Scholar
  146. Janssen, P. A. J.: 1965. The evolution of the butyrophenones, haloperidol and trifluperidol from meperidine like 4-phenylpiperidines, Int. Rev. Neurobiol. 8: 221–263.PubMedCrossRefGoogle Scholar
  147. Janssen, P. A. J.: 1967. Haloperidol and related butyrophenones, in: Psychopharmacological Agents ( M. Gordon, ed.), pp. 199–248, Academic Press, New York.Google Scholar
  148. Janssen, P. A. J.: 1973. Structure-activity relationships (SAR) and drug design as illustrated with neuroleptic drugs, in: Structure-Activity Relationships ( C. J. Cavalitto, ed.), pp. 37–73, International Encyclopedia of Pharmacology and Therapeutics, Pergamon Press, Oxford.Google Scholar
  149. Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L.: 1967. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? Part IV, Arzneimittel-Forsch. 17: 841–854.Google Scholar
  150. Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., Dresse, A., Lenaerts, F. M., Pinchard, A., Schaper, W. K. A., van Nueten, J. M., Verbruggen, F. J.: 1968. Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug, Arzneimittel-Forsch. 18: 261–279.Google Scholar
  151. Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., Lenaerts, F. M., Verbrulggen, F. J., van Nueten, J. M., Marsboom, R. H. M., Herin, V. V., Schaper, W. K. A.: 1970. The pharmacology of fluspirilene (R6218), a potent, long acting and injectable neuroleptic drug, Arzneimittel-Forsch. 20: 1689–1698.Google Scholar
  152. Jarrousse, M. J., Regnier, M. T.: 1951. Separation et activite physiologique des deux isomeres optiques du dimethylaminoethoxy-β-tolyphenylmethane, Ann. Pharm. Franc. 9: 321–325.PubMedGoogle Scholar
  153. Jones, R. G.: 1966. Chemistry of histamine and analogs: Relationship between structure and pharmacological activity, in: Histamine and Anti-histamines, Part 1 (O. Eichler, A. Farah, eds.), pp. 1–43, Vol. 18 of Handbook of Experimental Pharmacology, Springer, Berlin.Google Scholar
  154. Kamenar, B., Prout, K., Ganellin, C. R.: 1973. Crystal and molecular structure of the histamine H2-receptor antagonist N-(4-imidazol-4-ylbutyl)-N-methyl thiourea (burimamide), J. Chem. Soc. (Perkin Trans.) 11: 1734–1739.CrossRefGoogle Scholar
  155. Katz, R., Heller, S. R., Jacobson, A. E.: 1973. A molecular orbital study of norepinephrine and 3,4-dihydroxyphenethylamine: A re-evolution of structure-activity relationships in norepinephrine, Mol. Pharmacol. 9: 486–494.PubMedGoogle Scholar
  156. Kebabian, J. W., Petzold, G. L., Greengard, P.: 1972. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain and its similarity to the “dopamine receptor,” Proc. Natl. Acad. Sci. 69: 2145–2149.PubMedCrossRefGoogle Scholar
  157. Kerkut, G. A.: 1973. Catecholamines in invertebrates, Brit. Med. Bull. 29: 100–104.PubMedGoogle Scholar
  158. Kerkut, G. A., Walker, R. J.: 1961. The effects of drugs on the neurones of the snail, Helix aspersa, Comp. Biochem. Physiol. 3: 143–160.Google Scholar
  159. Kier, L. B.: 1967. Molecular orbital calculation of preferred conformations of acetylcholine, muscarine and muscarone, Mol. Pharmacol. 3: 487–494.PubMedGoogle Scholar
  160. Kier, L. B.: 1968a. Preferred conformation of serotonin and a postulate on the nature of its receptor from molecular orbital calculations, J. Pharm. Sci. 57: 1188–1191.PubMedCrossRefGoogle Scholar
  161. Kier, L. B.: 1968b. Molecular orbital calculations of the preferred conformations of histamine and a theory on its dual activity, J. Med. Chem. 11: 441–445.PubMedCrossRefGoogle Scholar
  162. Klein, D. F., Davis, J. M.: 1969. Diagnosis and Treatment of Psychiatric Disorders, Williams and Wilkins, Baltimore.Google Scholar
  163. Koch, M. H. J.: 1973. 4-(4-Chloro-a, a, a-trifluoro-m-tolyl)-l-[4,4-bis-(-fluorophenyl)butyl]-4- piperidinol (penfluridol), Acta Crystallog. B29: 1538–1540.Google Scholar
  164. Koch, M. H. J., Germain, G.: 1972. The crystal and molecular structure of 4’-fluoro-4-(1- [4-hydroxy-4-(4’-fluoro)-phenylpiperidinol])butyrophenone and its hydrochloride, Acta Crystallog. B28: 121–125.CrossRefGoogle Scholar
  165. Korolkovas, A.: 1970. In: Essentials of Molecular Pharmacology: Background for Drug Design, Wiley, New York.Google Scholar
  166. Koshland, D. E.: 1958. Application of a theory of enzyme specificity to protein synthesis, Proc. Natl. Acad. Sci. 44: 98–104.PubMedCrossRefGoogle Scholar
  167. Kvam, D. C., Riggilo, D. A., Lish, P. M.: 1965. Effect of some new α-adrenergic blocking agents on certain metabolic responses to catecholamines, J. Pharmacol. Exp. Ther. 149: 183–192.PubMedGoogle Scholar
  168. Lal, S., Sourkes, T. L.: 1972. Effects of various chlorpromazine metabolites on amphetamine induced stereotyped behaviour in the rat, Eur. J. Pharmacol. 17: 283–286.PubMedCrossRefGoogle Scholar
  169. Lands, A. M.: 1951. An investigation of the molecular configurations favorable for stimulation or blockade of the acetylcholine-sensitive receptors of visceral organs, J. Pharmacol. Exp. Ther. 102: 219–236.PubMedGoogle Scholar
  170. Lands, A.M.: 1952a. The cardiovascular actions of l-β-aminophenyl)-2-aminoethanol and related compounds, J. Pharmacol. Exp. Ther. 104: 474–477.PubMedGoogle Scholar
  171. Lands, A. M.: 1952b. The effect on blood pressure and toxicity of l-β-fluorophenyl)-2- aminoethanol and related compounds, J. Pharmacol. Exp. Ther. 106: 440–443.PubMedGoogle Scholar
  172. Lands, A. M., Brown, T. G.: 1967. Sympathomimetic (adrenergic) stimulants, in: Drugs Affecting the Peripheral Nervous System ( A. Burger, ed.), pp. 399–472, Dekker, New York.Google Scholar
  173. Lands, A. M., Cavallito, C. J.: 1954. An evaluation of the factors favorable for acetylcholine like stimulation by employing a series of quaternary ammonium alkyl sulfide and sulfoxide compounds, J. Pharmacol. Exp. Ther. 110: 369–384.PubMedGoogle Scholar
  174. Lands, A. M., Grant, J. I.: 1952. The vasopressor action and toxicity of cyclohexylethylamine derivatives, J. Pharmacol. Exp. Ther. 106: 341–345.PubMedGoogle Scholar
  175. Lands, A. M., Luduena, F. P.: 1956. The cholinolytic action of substituted dialkylaminoalkanes and dialkylaminoalkanols, J. Pharmacol. Exp. Ther. 116: 177–190.PubMedGoogle Scholar
  176. Lands, A. M., Tainter, M. I.: 1953. The effect of changes in molecular configuration on inhibitory sympathomimetic action, Arch. Exp. Pathol. Pharmakol. 219: 76–96.Google Scholar
  177. Lands, A. M., Nash, V. L., Mccarthy, H. M., Granger, H. R., Dertinger, B. L.: 1947a. The pharmacology of N-alkyl homologues of epinephrine, J. Pharmacol. Exp. Ther. 90: 110–119.PubMedGoogle Scholar
  178. Lands, A. M., Nash, V. L., Granger, H. R., Dertinger, B. L.: 1947b. The pharmacologic activity of N-methyl-ß-cyclohexyl-isopropylamine HC1, J. Pharmacol. Exp. Ther. 89: 383–385.Google Scholar
  179. Lands, A. M., Nash, V. L., Dertinger, B. L., Granger, H. R., Mccarthy, H. M.: 1948. The pharmacology of compounds structurally related to hydroxytryptamine, J. Pharmacol. Exp. Ther. 92: 369–380.PubMedGoogle Scholar
  180. Langer, S. Z., Rubio, M. C.: 1973. Effects of the noradrenaline metabolites on the adrenergic receptors, Naunyn Schmiedebergs Arch. Pharmakol. 276: 71–88.CrossRefGoogle Scholar
  181. Larsen, A. A., Gould, W. A., Roth, H. R., Comer, W. T., Uloth, R. H., Dungan, K. W., Lish, P. M.: 1967. Sulfonanilides. II. Analogs of Catecholamines, J. Med. chem. 10: 462–472.PubMedCrossRefGoogle Scholar
  182. Laverty, R., Sharman, D. H.: 1965. Modification by drugs of the metabolism of 3,4-dihydroxy phenylethylamine, noradrenaline and 5-hydroxytryptamine in the brain, Brit. J. Pharmacol. 24: 759–772.PubMedGoogle Scholar
  183. Lehmann, G., Randall, L. O.: 1948. Pharmacological properties of sympathomimetic diamines, J. Pharmacol. Exp. Ther. 93: 115–125.Google Scholar
  184. Leonard, F., Huttrer, C. P.: 1956. Histamine Antagonists, Chemical Biological Coordination Center, National Research Council, Washington, D.C.Google Scholar
  185. Lewis, J. J., Muir, T. C.: 1967. Drugs acting at nerve-skeletal muscle junctions, in: Drugs Affecting the Peripheral Nervous System (A. Burger, ed.), pp. 327–364, Dekker, New York.Google Scholar
  186. Liquori, A. M., Damiani, A., Elefante, G.: 1968a. Calculated minimum energy conformations of muscarine, J. Mol. Biol. 33: 439–444.PubMedCrossRefGoogle Scholar
  187. Liqouri, A. M., Damiani, A., Decoen, J. L.: 1968b. Calculated minimum energy conformations of acetylcholine, J. Mol. Biol. 33: 445–450.CrossRefGoogle Scholar
  188. Loew, E. R.: 1947. Pharmacology of antihistamine compounds, Physiol. Rev. 27: 542–573.PubMedGoogle Scholar
  189. Loewi, O.: 1921. Uber humor ale Ubertragbarkeit der Herznervenwirkung. I. Milleilung, Pfluegers Arch. Ges. Physiol. 189: 239–242.CrossRefGoogle Scholar
  190. Marsh, D. F., Howard, A., Herring, D. A.: 1951. The comparative pharmacology of the isomeric nitrogen methyl substituted heptylamines, J. Pharmacol. Exp. Ther. 103: 325–329.PubMedGoogle Scholar
  191. Marszak, I., Olomucki, M., Epsztein, R., Jacob, J.: 1954. Unsaturated amines. IX. Synthesis and parasympathomimetic properties of ethylenic quaternary ammonium salts, Comp. Rend. Acad. Sci. Paris 238: 166–168.Google Scholar
  192. Matthysse, S.: 1973. Antipsychotic drug actions: A clue to the neuropathology of schizophrenia? Fed. Proc. 32: 200–205.PubMedGoogle Scholar
  193. Mayer, S. E., Stull, J. T.: 1971. Cyclic AMP in Skeletal Muscle, Ann. N.Y. Acad. Sci. 185: 433–448.PubMedCrossRefGoogle Scholar
  194. Mcdowell, J. J. H.: 1969. The crystal and molecular structure of chlorpromazine, Acta Crystallog. B25: 2175–2181.CrossRefGoogle Scholar
  195. Mcgeer, E. G., Mcgeer, P. L., Mclennan, H.: 1961. The inhibitory action of δ-hydroxytryptamine, gamma-aminobutyric acid (GABA) and some other compounds towards the crayfish stretch receptor neuron, J. Neurochem. 8: 36–49.CrossRefGoogle Scholar
  196. Mcisaac, W. M., Page, I. H.: 1958. New metabolites of serotonin in carcinoid urine, Science 128: 537.PubMedCrossRefGoogle Scholar
  197. Mcnay, J. L., Mcdonald, R. H., Goldberg, L. I.: 1965. Direct renal vasodilation produced by dopamine in the dog, Circ. Res. 16: 510–517.PubMedGoogle Scholar
  198. Melville, K. I.: 1973. Antihistamine drugs, in: Histamine and Antihistamines ( M. Schachter, ed.), pp. 127–171, International Encyclopedia of Pharmacology and Therapeutics, Pergamon Press, Oxford.Google Scholar
  199. Miller, R. J., Hiley, C. R.: 1974. Relation of anti-muscarinic properties of neuroleptics to drug induced parkinsonism, Nature 248: 596–597.PubMedCrossRefGoogle Scholar
  200. Miller, R. J., Iversen, L. L.: 1974. Effect of psychoactive drugs on dopamine (3,4- dihydroxyphenethylamine)-sensitive adenylate cyclase activity in corpus striatum of rat brain, Biochem. Soc. Trans. 1: 90–93.Google Scholar
  201. Moe, G. K., Freyburger, W. A.: 1950. Ganglionic Blocking Agents, Pharmacol. Rev. 2: 61–95.Google Scholar
  202. Moller-Nielsen, I., Hougs, W., Lassen, N., Holm, T., Petersen, P. V.: 1962. Central Depressant Activity of Some Thiaxanthene Derivatives, Acta Pharmacol. Toxicol. 19: 87–100.CrossRefGoogle Scholar
  203. Moller-Nielsen, I., Pedersen, V., Nymark, M., Franck, K. F., Boeck, V., Fjallan, B., Christensen, A. V.: 1973. The Comparative Pharmacology of Flupenthixol and Some Reference Neuroleptics, Acta Pharmacol. Toxicol. 33: 353–362.CrossRefGoogle Scholar
  204. Nachod, F. C., Lands, A. M.: 1953. Relationship between chemical structure and biological activity of compounds with atropine-like activity, Trans. N.Y. Acad. Sci. 16: 2–13.PubMedCrossRefGoogle Scholar
  205. Nauta, W. T., Rekker, R. F., Harms, A. F.: 1968. Diarylcarbinolethers: Structure-activity relationships. A physico-chemical approach, in: Proceedings of the Third International Pharmacology Meeting, Vol. 7, pp. 305–325, Pergamon Press, New York.Google Scholar
  206. Nogradi, M., Ollis, W. D., Sutherland, I. D.: 1970. The conformational inversion of 2,3:6,7-dibenzo-derivatives of cycloheptatriene, tropone, heptafulvene, oxepin, thiepin and azepin, Chem. Commun. 1970: 158–160.Google Scholar
  207. Nyback, H.: 1971. Regional disappearance of catecholamines formed from 14C-tyrosine in rat brain: Effect of synthesis inhibitors and of chlorpromazine, Acta Pharmacol. Toxicol. 30: 372–384.CrossRefGoogle Scholar
  208. Nyback, H., Sedvall, G.: 1968. Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain, J. Pharmacol. Exp. Ther. 162: 294–301.PubMedGoogle Scholar
  209. Nyback, H., Sedvall, G.: 1972. Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from I4C-tyrosine in mouse brain, Psychopharmacologia 26: 155–160.PubMedCrossRefGoogle Scholar
  210. Osborne, M., Detar, R., Gabel, L.: 1962. Comparison between the autonomic pharmacology of 5-hydroxytryptamine and 5-acetyltryptamine (5-AT), Fed. Proc. 21: 324.Google Scholar
  211. Paton, W. D. M., Zaimis, E. J.: 1952. The methonium compounds, Pharmacol. Rev. 4: 219–253.PubMedGoogle Scholar
  212. Pauling, P., Petcher, T. J.: 1973. Neuromuscular blocking agents: Structures and activity, Chem. Biol. Interact. 6: 351–365.PubMedCrossRefGoogle Scholar
  213. Pederson, L., Hoskins, R. E., Cable, H.: 1971. The preferred conformation of noradrenaline, J. Pharm. Pharmacol. 23: 216–218.CrossRefGoogle Scholar
  214. Periti, P. F.: 1970. On active conformation of histamine and analogues, Pharmacol. Res. Commun. 2: 309–318.CrossRefGoogle Scholar
  215. Petersen, P. V., Moller-Nielsen, I.: 1964. Thioxanthene derivatives, in: Psychopharmacological Agents, Vol. 1 ( M. Gordon, ed.), pp. 301–324, Academic Press, New York.Google Scholar
  216. Phillis, J. W., Tebecis, A. K.: 1967. The responses of thalamic neurones to iontophoretically applied monoamines, J. Physiol. 192: 715–745.PubMedGoogle Scholar
  217. Post, M. L., Kennard, O., Horn, A. S.: 1974. 2-Chloro-9-(w-dimethyl- aminopropylidene)thioxanthene, Acta Crystallog B30: 1644–1646.Google Scholar
  218. Powell, C. E., Slater, I. H.: 1958. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol, J. Pharmacol. Exp. Ther. 122: 480–488.PubMedGoogle Scholar
  219. Pratesi, P., La Manna, A., Campiglio, A., Ghislandi, V.: 1958. The configuration of adrenaline and of its β-hydroxyphenyl analogue, J. Chem. Soc. 1958: 2069–2074.CrossRefGoogle Scholar
  220. Pratesi, P., La Manna, A., Campiglio, A., Ghislandi, V.: 1959. The configuration of Noradrenaline, J. Chem. Soc. 1959: 4062–4065.CrossRefGoogle Scholar
  221. Pullman, B., Courriere, P., Coubeils, J. L.: 1971. Quantum mechanical study of the conformational and electronic properties of acetylcholine and its agonists muscarine and nicotine, Mol. Pharmacol. 7: 397–405.PubMedGoogle Scholar
  222. Pullman, B., Coubeils, J. L., Courriere, P., Gervois, J. P.: 1972. Quantum mechanical study of the conformation properties of phenethylamines of biochemical and medical interest, J. Med. Chem. 15: 17–23.PubMedCrossRefGoogle Scholar
  223. Randrup, A., Munkvad, I.: 1970. Biochemical anatomical and psychological investigations of stereotyped behavior induced by amphetamines, in: Amphetamines and Related Compounds ( E. Costa, S. Garattini, eds.), pp. 695–713, Raven Press, New York.Google Scholar
  224. Randrup, A., Scheel-Kruger, J.: 1966. Diethyldithiocarbamate and amphetamine stereotype behaviour, J. Pharm. Pharmacol. 18: 752.PubMedCrossRefGoogle Scholar
  225. Randrup, A., Munkvad, I., Udsen, P.: 1963. Adrenergic mechanisms and amphetamine induced abnormal behaviour, Acta Pharmacol. Toxicol. 20: 145–157.CrossRefGoogle Scholar
  226. Reed, L. L., Schaefer, J. P.: 1973. The crystal and molecular structure of haloperidol, a potent psychotropic drug, Acta Crystallog. 829: 1886–1890.Google Scholar
  227. Renshaw, R. R., Hopkins, C. T.: 1929. Phosphoric acid ester derivatives of choline: Basis for the psychological activity of -onium compounds, J. Am. Chem. Soc. 51: 953–964.CrossRefGoogle Scholar
  228. Renshaw, R. R., Hunt, R.: 1929. The pharmacological action of some homologues of betaine and choline esters, J. Pharmacol. Exp. Ther. 37: 309–337.Google Scholar
  229. Renshaw, R. R., Dreisbach, P. F., Ziff, M., Green, D.: 1938. Thioesters of choline and O-methylcholine and their psychological activity: Onium compounds, J. Am. Chem. Soc. 60: 1765–1770.CrossRefGoogle Scholar
  230. Robison, G. A., Butcher, R. W., Sutherland, E. W.: 1967. Adenylcyclase as an adrenergic receptor, Ann. N.Y. Acad. Sci. 139: 703–723.PubMedCrossRefGoogle Scholar
  231. Robison, G. A., Butcher, R. W., Sutherland, E. W.: 1971. Cyclic AMP, p. 225, Academic Press, New York.Google Scholar
  232. Rocha, E., Silva, M.: 1960. Influence of pH on the interaction of histamine with its receptors in the guinea pig ileum, Arch. Int. Pharmacodyn. 128: 355–374.Google Scholar
  233. Saavedra, J. M., Brownstein, M., Axelrod, J.: 1973. A specific and sensitive enzymaticisotopic microassay for serotonin in tissues, J. Pharmacol. Exp. Ther. 186: 508–515.PubMedGoogle Scholar
  234. Salle, J.: 1952. The pharmacology of fluroacetylcholine bromide, Arch. Int. Pharmacodyn. 91: 339–349.PubMedGoogle Scholar
  235. Sastry, B. V. R., Pfeiffer, C. C., Lasslo, A.: 1960. Relation between chemical constitution and biological response of D(—), L(+) and DL-lactoylcholines and related compounds, J. Pharmacol. Exp. Ther. 130: 346–355.PubMedGoogle Scholar
  236. Schaefer, J. P.: 1967. The structure of thiothixene, Chem. Commun. 1967: 743–744.Google Scholar
  237. Scheel-Kruger, J.: 1972. Behavioural and biochemical comparison of amphetamine derivatives, cocaine, benztropine and tricyclic antidepressant drugs, Eur. J. Pharmacol. 18: 63–73.PubMedCrossRefGoogle Scholar
  238. Schmiedeberg, O., Koppe, R.: 1869. Das Muscarine, das Giftige Alkaloid des Fliegenpilzes, Vogel, Leipzig.Google Scholar
  239. Schueler, F. W.: 1953. The statistical nature of the intramolecular distance factor of the muscarinic moiety, Arch. Int. Pharmacodyn. 93: 417–426.PubMedGoogle Scholar
  240. Schueler, F. W., Hanna, C.: 1951. The pharmacological activities of some hydrazonium analogs related to acetylcholine tetramethylammonium and tetraethylammonium, Arch. Int. Pharmacodyn. 88: 351–360.Google Scholar
  241. Schueler, F. W., Keasling, H. H.: 1951. Further studies on the RC (reversed carboxyl) analog of acetylcholine and some additional derivatives, J. Pharmacol. Exp. Ther. 103: 222–235.PubMedGoogle Scholar
  242. Scott, K. A., Mautner, H. G.: 1967. Sulfur and selenium isologs related to acetylcholine and choline-IX, Biochem. Pharmacol. 16: 1903–1918.PubMedCrossRefGoogle Scholar
  243. Shader, R. I., Dimascio, A.: 1970. Psychotropic Drug Side Effects, Williams and Wilkins, Baltimore.Google Scholar
  244. Shefter, E., Triggle, D. T.: 1970. Is there a unique conformation of cholinergic ligands responsible for muscarinic activity? Nature 227: 1354–1355.PubMedCrossRefGoogle Scholar
  245. Sheppard, H., Burghardt, C., Greengard, P.: 1973. The interaction of dopamine and its derivatives with the dopamine-sensitive adenylate cyclase of rat caudate nucleus, Pharmacologist 15: 231.Google Scholar
  246. Simonart, A.: 1932, On the action of certain derivatives of choline, J. Pharmacol. Exp. Ther. 46: 157–193.Google Scholar
  247. Simonart, A.: 1934. Contribution a l’etude des? alkyl cholines, Arch. Int. Pharmacodyn. 48: 328–332.Google Scholar
  248. Simpson, T. R. Jr., Craig, J. C., Kumler, W. D.: 1967. Determination of the conformation of nicotine and some related compounds by nuclear magnetic resonance and dipole moments, J. Pharm. Sci. 56: 708–713.PubMedCrossRefGoogle Scholar
  249. Singhgrewal, R.: 1952. The pharmacological actions of 6-methyladrenaline, Brit. J. Pharmacol. 7: 338–348.Google Scholar
  250. Snyder, S. H.: 1972. Catecholamines in the brain as mediators of amphetamine psychosis, Arch. Gen. Psychiat. 27: 169–179.PubMedCrossRefGoogle Scholar
  251. Snyder, S. H., Greenberg, D., Yamamura, H. I.: 1974. Antischizophrenicdrugsandbrain cholinergic receptors: Affinity for muscarinic sites predicts extrapyramidal effects, Arch. Gen. Psychiat., 31: 58–61.PubMedCrossRefGoogle Scholar
  252. Soudijn, W., van Wijngaarden, I.: 1972. Localization of 3H-pimozide in the rat brain in relation to its anti-amphetamine potency, J. Pharm. Pharmacol. 24: 773–780.PubMedCrossRefGoogle Scholar
  253. Stehle, R. L., Melville, K. I., Oldham, F. K.: 1936. Choline as a factor in the elaboration of adrenaline, J. Pharmacol. Exp. Ther. 56: 473–481.Google Scholar
  254. Stenlake, J. B.: 1963. Some chemical aspects of neuromuscular block, in: Progress in Medicinal Chemistry, Vol. 3 ( G. P. Ellis, G. B. West, eds.), pp. 1–51, Butterworth, London.Google Scholar
  255. Stoll, H. C.: 1948. Pharmacodynamic considerations of atropine and related compounds, Am. J. Med. Sci. 215: 577–592.PubMedGoogle Scholar
  256. Swanson, E. E., Chen, K. K.: 1946. Comparison of pressor action of aliphatic amines, J. Pharmacol. Exp. Ther. 88: 10–13.PubMedGoogle Scholar
  257. Swanson, E. E., Steldt, F. A., Chen, K. K.: 1945. Further observations on the pressor action of optical isomers of sympathomimetic amines, J. Pharmacol. Exp. Ther. 85: 70–73.PubMedGoogle Scholar
  258. Taylor, D. B., Nederguard, O. A.: 1965. Relation between structure and action of quaternary ammonium neuromuscular blocking agents, Physiol. Rev. 45: 523–554.PubMedGoogle Scholar
  259. Testa, B., Jenner, P.: 1973. Circular dichroic determination of the preferred conformation of nicotine and related chiral alkaloids in aqueous solution, Mol. Pharmacol. 9: 10–16.PubMedGoogle Scholar
  260. Trendelenburg, U.: 1956. The action of 5-hydroxytryptamine on the nictitating membrane and on the superior cervical ganglion of the cat, Brit. J. Pharmacol. 11: 74–80.PubMedGoogle Scholar
  261. Trendelenburg, U.: 1957. The action of morphine on the superior cervical ganglion and on the nictitating membrane of the cat, Brit. J. Pharmacol. 12: 79–85.PubMedGoogle Scholar
  262. Trendelenburg, U., Muskus, A., Fleming, W. W., Alonso, S. B. G.: 1962. Modification by reserpine of the action of sympathomimetic amines in spinal cats; a classification of sympathomimetic amines, J. Pharmacol. Exp. Ther. 138: 170–180.PubMedGoogle Scholar
  263. Triggle, D. J.: 1970. Adrenergic hormones and drugs, in: Medicinal Chemistry, Vol. II ( A. Burger, ed.), pp. 1235–1295, Wiley-Interscience, New York.Google Scholar
  264. Triggle, D. J.: 1971. Neurotransmitter-Receptor Interactions, Academic Press, London.Google Scholar
  265. Triggle, D. J.: 1972. Adrenergic receptors, Ann. Rev. Pharmacol. 12: 185–196.PubMedCrossRefGoogle Scholar
  266. Turtle, J. R., Kipnis, D. M.: 1967. An adrenergic receptor mechanism for the control of cyclic 3’,5’-adenosine monophosphate systems in tissue, Biochem. Biophys. Res. Commun. 28: 797–802.PubMedCrossRefGoogle Scholar
  267. Ungerstedt, U.: 1971. Stereotaxic mapping of the monoamine pathways in the rat brain, Acta Physiol. Scand. Suppl. 376: 1–48.Google Scholar
  268. Urech, E., Marxer, A., Miescher, K.: 1950. Aminoalkyl-imidazoline, Helv. Chim. Acta 33: 1386–1407.CrossRefGoogle Scholar
  269. Vane, J. R.: 1957. A sensitive method for the assay of 5-hydroxytryptamine, Brit. J. Pharmacol. 12: 344–349.PubMedGoogle Scholar
  270. Vane, J. R.: 1959. The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation, Brit. J. Pharmacol. 14: 87–98.PubMedGoogle Scholar
  271. van Rossum, J. M.: 1962. Pharmacodynamics of parasympathetic drugs: Mechanism of action and structure action of tertiary ammonium salts, Arch. Int. Pharmacodyn. 140: 592–605.PubMedGoogle Scholar
  272. van Rossum, J. M., Ariens, E. J.: 1959. Pharmacodynamics of parasympathetic drugs: Structure-action relations in homologous series of quaternary ammonium salts, Arch. Int. Pharmacodyn. 118: 418–446.Google Scholar
  273. Waser, P. G.: 1961. Chemistry and pharmacology of muscarine, muscarone and some related compounds, Pharmacol. Rev. 13: 465–515.PubMedGoogle Scholar
  274. Weissman, A., Koe, K. B., Tenen, S. S.: 1966. Antiamphetamine effects following inhibition of tyrosine hydroxylase, J. Pharmacol. Exp. Ther. 151: 339–352.PubMedGoogle Scholar
  275. Welch, A. D., Roepke, M. H.: 1935. A comparative study of choline and certain of its analogues, J. Pharmacol. Exp. Ther. 55: 118–126.Google Scholar
  276. Welsh, J. H., Taub, R.: 1951. The significance of the carbonyl group and ether oxygen in the reaction of Ach with receptor substance, J. Pharmacol. Exp. Ther. 103: 62–73.PubMedGoogle Scholar
  277. Werner, L. H., Barrett, W. E.: 1967. In: Antihypertensive Agents (E. Schlittler, ed.), pp. 331–392, Academic Press, New York.Google Scholar
  278. Whittaker, V. P.: 1963. In: Handbook of Experimental Pharmacology, Vol. 15 (G. B. Koelle, ed.), pp. 1–39, Springer, Berlin.Google Scholar
  279. Wilkinson, S.: 1961. The history and chemistry of muscarine, Quart. Rev. Chem. Soc. 15: 153–171.CrossRefGoogle Scholar
  280. Woodruff, G. N.: 1971. Dopamine Receptors: A review, Comp. Gen. Pharmacol. 2: 439–455.PubMedCrossRefGoogle Scholar
  281. Woodruff, G. N., Walker, R. J.: 1969. The effect of dopamine and other compounds on the activity of neurones of Helix aspersa: Structure-activity relationships, Int. J. Neuropharmacol. 8: 279–289.PubMedCrossRefGoogle Scholar
  282. Woolley, D. W.: 1959. Highly potent antimetabolites of serotonin with litde serotonin-like action, Biochem. Pharmacol. 1: 51–59.CrossRefGoogle Scholar
  283. Woolley, D. W., Campbell, N. K.: 1962. Serotonin-like and antiserotonin properties of psilocybin and psilocin, Science 136: 777–779.PubMedCrossRefGoogle Scholar
  284. Wurzel, M.: 1959. A suggested mechanism for the action of choline esters on animal organs, inferred from a study of the effects of choline, J-methylcholine and thiocholine-esters, Experientia 15: 430–433.CrossRefGoogle Scholar
  285. Yamamoto, C.: 1967. Pharmacologic studies of norepinephrine, acetylcholine and related compounds on neurons in Deiters’ nucleus and the cerebellum, J. Pharmacol. Exp. Ther. 156: 39–47.PubMedGoogle Scholar
  286. Yamamura, H. I., Snyder, S. H.: 1974. Muscarinic cholinergic receptor binding in rat brain, Prox. Natl. Acad. Sci., 71: 1725–1729.CrossRefGoogle Scholar
  287. Yeh, B. K., Mcnay, J. L., Goldberg, L. I.: 1969. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: Evidence of a specific dopamine receptor, J. Pharmacol. Exp. Ther. 168: 303–309.PubMedGoogle Scholar
  288. Zirkle, C. L., Kaiser, C.: 1970. Antipsychotic agents, in: Medicinal Chemistry, Vol. 11 (A. Burger, ed.), pp. 1410–1469, Wiley-InterScience, New York.Google Scholar

Copyright information

© Plenum Press, New York 1975

Authors and Affiliations

  1. 1.MRC Neurochemical Pharmacology Unit, Department of PharmacologyUniversity of CambridgeCambridgeEngland

Personalised recommendations